DB16443InvestigationalVaccines
The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a baculovirus expression system . In pre-clinical trial testing on mice, rabbits, and... In pre-clinical trial testing on mice, rabbits, and non-human primates, the candidate was able to induce a functional antibody response within 7-14 days of initial injection.
- Code names
- Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)
What you can answer from here — as of January 18, 2021
Which companies are running trials of Recombinant SARS-CoV-2 Vaccine (Sf9 Cell), in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account